SEC Filings :: Cabaletta Bio, Inc. (CABA)

Contact

Our RESET^TM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.

Latest Quarterly or Annual Filing

November 14, 2024

Quarterly report pursuant to Section 13 or 15(d)

Earnings Release

10-Q

PDF HTML

XBRL

ZIP XLS HTML

View PDF View HTML

Latest Current Report

November 18, 2024

Current report filing

View PDF View HTML

Latest Proxy Statement

April 23, 2024

Definitive proxy statements

View PDF View HTML

View All SEC Filings

View and filter by group or type

View All Filings